IMMUNOCHARGING
DEAD

Serial Number

90326590

Owner

CELULARITY, INC.

Attorney

Camille M. Miller

Filing Date

Nov 18, 2020

Add to watchlist:

No watchlists yet
View on USPTO

IMMUNOCHARGING Trademark

Serial Number: 90326590

IMMUNOCHARGING is a trademark filed by CELULARITY, INC. on November 18, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

CELULARITY, INC. (50 trademarks)

33 TECHNOLOGY DRIVE
WARREN, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

November 18, 2020

Registration Date

Not Registered

Published for Opposition

June 8, 2021

Goods & Services

Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, umbilical cord cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; surgical implants comprised of living tissue, namely, human amniotic membrane and human chorionic membrane intended for subsequent implantation; surgical implants comprised of living tissue, namely, human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use in the nature of biological preparations, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for treating cancer or other disease-associated antigen; pharmaceutical preparations for wounds, namely, biological tissue intended for use as a wound covering; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds; written instructional materials distributed in connection with the aforesaid goods packaged with the goods; biological products for medical use, namely, biological preparations in the nature of placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for treatment of cancer or other disease-associated antigen

Bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research

Research, development and testing services for others in the fields of genomics, biotechnology and pharmaceuticals; stem cell research services; research, development and testing services in the fields of genomics, biotechnology and pharmaceuticals, namely, collection, testing, processing, preservation, storage and retrieval of cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; laboratory research services in the field of genomics, biotechnology and pharmaceuticals consisting of collection, testing, processing, preservation, storage and retrieval of bioengineered cells, human allograft tissue made from human umbilical cords and human placentas, human amniotic membrane and human chorionic membrane, human collagen and extracellular matrix compositions; providing technical writing and a website featuring information in the field of medical research relating to banking stem cells and cord blood banking; biological research, namely, biosourcing of clinically accessible, immune-tolerant human stem and progenitor and other postpartum placenta-derived cell populations and tissues for medical research; medical research to find methods to restore the structure and function of damaged or diseased tissues and organs, including wound care, reconstructive medicine, whole organ and tissue regeneration and renewal; medical research regarding emergent cell therapies; medical research regarding allogeneic immunotherapy; providing on-line information, news and commentary in the field of medical research relating to the foregoing

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 5, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 4, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 29, 2022 EXRA
SOU EXTENSION 3 GRANTED
Dec 27, 2022 EX3G
SOU EXTENSION 3 FILED
Dec 27, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 27, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 7, 2022 EXRA
SOU EXTENSION 2 GRANTED
Jul 5, 2022 EX2G
SOU EXTENSION 2 FILED
Jul 5, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 5, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2022 EXRA
SOU EXTENSION 1 GRANTED
Jan 3, 2022 EX1G
SOU EXTENSION 1 FILED
Jan 3, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 3, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 3, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 8, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 8, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 19, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 3, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
May 3, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 3, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
May 3, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 3, 2021 CNEA
ASSIGNED TO EXAMINER
Apr 30, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 21, 2021 NWOS
NEW APPLICATION ENTERED
Nov 21, 2020 NWAP